Air Doctor
+9%
est. 2Y upside i
Rank
#1853
Sector
HealthTech
Est. Liquidity
~2Y
Data Quality
Data: LowAir Doctor shows high growth and strong moat, but significant incumbent threat and a stale valuation from a Series B round 20 months ago make the equity highly risky.
Last updated: July 3, 2026
Revenue grows to ~$39M; exit multiple holds at 10x driven by IPO window and category leadership, resulting in $392M exit. After dilution, net upside ~272%.
Revenue grows to ~$39M; exit multiple converges to 3x (public comp range), implying $118M exit. After dilution and preference, net upside slightly negative at -2.4%.
Revenue grows to ~$39M but exit multiple compresses to 1x, implying $39M exit, below $50.9M preferred stack. Common stock recovers -100%.
Preference Stack Risk
severeFunding Intensity
50900%Total preferred liquidation preference of $50.9M represents ~51% of the estimated entry valuation.
Dilution Risk
highHigh cash burn implies another round needed within 2 years, likely diluting common by ~20%.
Secondary Liquidity
noneNo secondary market activity reported.
Questions to Ask at the Interview
Strategic questions based on Air Doctor's data — designed to show you've done your homework.
- 1
“How does Air Doctor plan to defend against large incumbents like AXA and Teladoc?”
- 2
“What is the path to profitability given the high growth and commission-based model?”
- 3
“Given the stale valuation and need for funding, what is your comfort level with equity dilution?”
Community
Valuation Sentiment
Our model estimates +9% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.